Rumeurs, idées reçues, clichés, superstitions, légende : qui dit vrai ? qui dit faux ?
Cameroon Allocates XAF155.4 Million for Malaria Vaccine Purchase

Cameroon Allocates XAF155.4 Million for Malaria Vaccine Purchase

Paru le jeudi, 30 novembre 2023 13:15

The Cameroonian government has earmarked XAF155.4 million for the acquisition of 1,295,600 doses of malaria vaccine, which the country is expected to receive from its partners by the end of December 2023. This information is contained in a press release issued on Wednesday, November 29, by Manaouda Malachie, the Minister of Public Health (Minsanté).

"A dose is normally priced at $9.7, but as our request for the Gavi Alliance’s support was accepted in August 2023, Cameroon is contributing $0.2 for this first year," Minsanté explained. According to the Minister, Gavi is covering the remaining cost, amounting to XAF3.6 billion.

On November 21, Cameroon received its first batch of 331,200 doses of the RTS,S malaria vaccine (marketed under the brand name Mosquirix), manufactured by British pharmaceutical giant GSK. These doses cost Cameroon exactly XAF39,744,000, Manaouda Malachie stated, emphasizing that the vaccine will be used as an "additional control tool" against malaria.

He also reassured the public about the efficacy and safety of the vaccine, which will be administered to children aged between 6 and 24 months starting in 2024, despite some unfounded claims about its safety.

As a reminder, on December 2, 2021, Gavi's Board of Directors approved the implementation of a malaria vaccination program in African countries where the disease is endemic. This decision follows the recommendation of the World Health Organization (WHO) to administer the RTS,S vaccine to children living in areas of moderate to high transmission, with the aim of curbing infections with Plasmodium falciparum, the parasite responsible for the most deadly forms of malaria. Cameroon, one of the eleven countries most affected by malaria worldwide, is the first African country to receive the vaccine, following the pilot phase in Ghana, Kenya, and Malawi.

P.N.N

● Fact Cheking




● E-SCAMS


 

Please publish modules in offcanvas position.